Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti–β-Amyloid Immunotherapy

The overall incidences of ARIA-E and ARIA-H were 6.5% and 7.8%, respectively, and the pooled proportion of asymptomatic ARIA was 80.4%. The cohorts treated with aducanumab showed a significantly higher incidence of ARIA-E and ARIA-H (30.7% and 30.0%) compared with other drugs.